According to the law firm press release, the complaint filed in this class action lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company\'s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company\'s CEO, and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; (2) that the Company lacked adequate checks and protections to prevent such behavior; and (3) that, as a result of the foregoing, Defendants\' statements about Akari\'s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Akari Therapeutics, Plc Securities Litigation
May 24, 2017 | Akari Therapeutics Plc NASDAQ: AKTX | Case Status: Settled
If you purchased a significant amount of shares of Akari Therapeutics Plc (NASDAQ: AKTX), you have certain options. Investors should register for updates.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Akari Therapeutics Plc
First Identified Complaint
Derek Da Ponte, et al. v. Akari Therapeutics, Plc, et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Class Action Complaint for Violations of the Federal Securities Laws||May 12th, 2017|